Abstract
Viscosupplementation in the treatment of osteoarthritis
Highlights
The “Bone Involvement in Arthritis” International Meeting was first held in Venice, in 2004, with the objective of bringing together distinguished international experts in the fields of bone metabolism and rheumatic diseases to discuss emerging knowledge regarding the interplay between rheumatic diseases and the bone tissue
Given the dramatic implications of these rare adverse events (AEs), a drug-free holiday should be considered in patients treated for more than 5 years with BPs, after an accurate evaluation of risks and benefits
Denosumab have been shown to produce a sustained increase of bone mineral density over 8 years of treatment, and to reduce the risk of new fragility fracture up to 5 years of continuous treatment
Summary
The “Bone Involvement in Arthritis” International Meeting was first held in Venice, in 2004, with the objective of bringing together distinguished international experts in the fields of bone metabolism and rheumatic diseases to discuss emerging knowledge regarding the interplay between rheumatic diseases and the bone tissue. Several pharmacological agents [bisphosphonates (BPs), SERMs, teriparatide, PTH 1-84, strontium ranelate, denosumab] have been approved worldwide for the prevention of fragility fractures in patients at risk. Some concerns have been raised about long-term safety of BPs, due to “unexpected” rare adverse events (AEs) potentially associated with their use (atypical fractures, ONJ and esophageal cancer).
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call